Results for “fatigue”
Chronic Fatigue Syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic illness characterized by profound fatigue, sleep disturbances, and cognitive impairments, with post-exertional malaise being a hallmark symptom. ## Overview Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic and debilitating illness that affects millions of people worldwide. Despite its prevalence, ME/CFS remains poorly understood, and its diagnosis and treatment are often shrouded in controversy. People with ME/CFS experience a wide range of symptoms, including fatigue that is not relieved by rest, sleep disturbances, memory and concentration problems, and pain. The most distinctive feature of ME/CFS is post-exertional malaise (PEM), a worsening of symptoms that can occur after even minor physical or mental activity. ME/CFS is often referred to as a "hidden" illness, as its symptoms can be subtle and may not be immediately apparent. However, the impact of ME/CFS on daily life can be profound, with many people experiencing significant limitations in their ability to work, engage in social activities, and participate in daily tasks. The exact cause of ME/CFS is still unknown, and there is no cure. However, research is ongoing to better understand the underlying mechanisms of the illness and to develop effective treatments. ## History/Background The term "chronic fatigue syndrome" (CFS) was first coined in the 1980s, although the illness itself has been described in medical literature for centuries. In the 19th century, the term "neurasthenia" was used to describe a condition characterized by fatigue, anxiety, and depression. In the 1950s and 1960s, the term "post-viral fatigue syndrome" was used to describe a condition that developed after viral infections. In the 1980s, the term "chronic fatigue syndrome" was adopted, and the illness was recognized as a distinct medical condition. In the 1990s, the term "myalgic encephalomyelitis" (ME) was reintroduced, and it is now widely used to describe the more severe form of the illness. ME/CFS is recognized as a chronic and debilitating condition by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Despite its recognition as a legitimate medical condition, ME/CFS remains poorly understood, and its diagnosis and treatment are often shrouded in controversy. ## Key Information * **Prevalence:** ME/CFS affects an estimated 836,000 to 2.5 million people in the United States alone. * **Symptoms:** Fatigue that is not relieved by rest, sleep disturbances, memory and concentration problems, pain, and post-exertional malaise (PEM). * **Causes:** Unknown, but may be related to viral infections, immune system dysfunction, and genetic predisposition. * **Diagnosis:** Based on a combination of medical history, physical examination, and laboratory tests. * **Treatment:** There is no cure, but symptoms can be managed with medication, lifestyle changes, and alternative therapies. * **Prognosis:** Variable, with some people experiencing a gradual improvement in symptoms over time, while others experience a worsening of symptoms. ## Significance ME/CFS is a significant public health concern, with a profound impact on the quality of life of those affected. The illness is often misunderstood, and people with ME/CFS may experience stigma, isolation, and lack of support. Research is ongoing to better understand the underlying mechanisms of ME/CFS and to develop effective treatments. In the meantime, it is essential to raise awareness about the illness and to provide support to those affected. INFOBOX: - Name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - Type: Chronic and debilitating illness - Date: Recognized as a legitimate medical condition by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) in the 1990s - Location: Affects people worldwide - Known For: Profound fatigue, sleep disturbances, memory and concentration problems, pain, and post-exertional malaise (PEM) TAGS: Chronic fatigue syndrome, myalgic encephalomyelitis, post-exertional malaise, fatigue, sleep disturbances, memory and concentration problems, pain, viral infections, immune system dysfunction, genetic predisposition, diagnosis, treatment, prognosis, public health concern, stigma, isolation, lack of support, research, awareness, support.
Health & MedicineFibromyalgia
** Fibromyalgia is a chronic, multisystem disorder marked by widespread musculoskeletal pain together with fatigue, cognitive difficulties, and a constellation of other symptoms that significantly impair quality of life. **CONTENT:** ## Overview Fibromyalgia (often abbreviated **FM**) is a long‑term health condition characterized primarily by **widespread chronic pain** that persists for at least three months and is felt on both sides of the body, above and below the waist. In addition to pain, individuals with FM commonly report **fatigue**, **unrefreshing sleep**, **cognitive disturbances** (sometimes called “fibro‑fog”), **headaches**, **depression**, and **abdominal cramping**. Current diagnostic criteria (the 2016 revisions of the American College of Rheumatology guidelines) require that patients not only meet a pain‑distribution threshold but also score above a set severity level on at least **one** of six associated symptom domains: fatigue, cognitive impairment, unrefreshed sleep, abdominal pain, depression, or headache. The condition is **non‑progressive**—it does not worsen structurally over time—but symptoms can fluctuate, with periods of relative remission alternating with flare‑ups. Because the **cause of fibromyalgia remains unknown**, it is classified as a **central sensitization syndrome**: the nervous system appears to amplify pain signals, and normal sensory inputs may be perceived as painful. This neurobiological model helps explain why patients often experience heightened sensitivity to temperature, pressure, and even light. Importantly, fibromyalgia is **not** a disease of the joints, muscles, or connective tissue; imaging and laboratory tests typically appear normal, which can lead to misdiagnosis or dismissal of symptoms. Early recognition and a multidisciplinary treatment plan—combining medication, physical therapy, cognitive‑behavioral strategies, and lifestyle modifications—are essential for improving function and reducing suffering. **If you experience persistent, widespread pain accompanied by the above symptoms, seek evaluation from a qualified health professional** such as a rheumatologist, primary‑care physician, or pain specialist. ## History/Background The term “fibromyalgia” was first coined in the **1970s**, merging the Greek words *fibro* (fibrous tissue) and *myalgia* (muscle pain). Early descriptions, however, date back to the 19th century when physicians noted “muscular rheumatism” in patients, especially women, who presented with diffuse pain without clear inflammatory markers. In **1990**, the American College of Rheumatology (ACR) introduced the first formal classification criteria, focusing on **tender point examination**—the presence of pain at 11 of 18 specific sites. This approach dominated research for two decades but was criticized for its subjectivity and exclusion of many patients whose pain patterns did not fit the tender‑point model. A major shift occurred in **2010** when the ACR released revised criteria that emphasized **symptom severity** and **widespread pain index**, allowing for a more inclusive diagnosis. Further refinements in **2016** added the requirement of at least one additional symptom domain (fatigue, cognition, sleep, etc.) to capture the syndrome’s multidimensional nature. Throughout the 2000s, advances in functional MRI and neurochemical studies revealed abnormal pain processing pathways, supporting the central sensitization hypothesis and moving fibromyalgia from a “psychogenic” label toward a recognized neurobiological disorder. ## Key Information - **Epidemiology:** Fibromyalgia affects **2–4 %** of the global population, with a striking female predominance (approximately 80–90 % of diagnosed cases). Onset most commonly occurs between ages **30–55**, though it can appear at any age, including adolescence. - **Diagnostic Criteria:** The 2016 ACR guidelines require (1) a **Widespread Pain Index (WPI) ≥ 7** or **WPI ≥ 4** plus a **Symptom Severity Scale (SSS) ≥ 5**, and (2) the presence of **≥ 1** of the six associated symptoms above a severity threshold. Symptoms must be present for at least **three months** and not be better explained by another medical condition. - **Pathophysiology Theories:** Proposed mechanisms include (a) **central sensitization** with heightened dorsal horn excitability, (b) dysregulation of **neurotransmitters** such as serotonin, norepinephrine, and substance‑P, (c) **hypothalamic‑pituitary‑adrenal (HPA) axis** dysfunction leading to abnormal stress responses, and (d) **genetic predisposition**—family studies suggest a heritable component. No single theory fully accounts for all clinical features. - **Treatment Options:** No cure exists, but a combination of **pharmacologic** (e.g., duloxetine, milnacipran, pregabalin), **non‑pharmacologic** (graded exercise, aerobic conditioning, tai chi, yoga), and **psychological** interventions (cognitive‑behavioral therapy, mindfulness) can reduce symptom burden. Patient education and self‑management strategies are critical. - **Comorbidities:** FM frequently co‑occurs with **irritable bowel syndrome, chronic fatigue syndrome, migraine, temporomandibular joint disorder, and mood disorders**. Recognizing these overlaps helps clinicians tailor comprehensive care plans. ## Significance Fibromyalgia matters because it represents a **major source of disability** worldwide, accounting for millions of lost workdays and substantial health‑care expenditures. Its **subjective nature** challenges clinicians, leading to delayed diagnosis—average time from symptom onset to diagnosis can exceed **5 years**. This delay exacerbates functional decline and psychological distress. By acknowledging fibromyalgia as a legitimate, biologically based condition, the medical community reduces stigma, encourages research funding, and improves access to multidisciplinary treatment. Moreover, insights gained from studying central sensitization have broader implications for other chronic pain syndromes, potentially guiding novel analgesic development and informing public health strategies aimed at **pain management** and **mental‑health integration**. Patients, families, and health‑care systems benefit when fibromyalgia is recognized early, managed holistically, and supported with evidence‑based interventions. If you or someone you know struggles with the hallmark symptoms, **prompt professional evaluation** is essential to rule out other conditions, obtain an accurate diagnosis, and begin an individualized treatment plan. **INFOBOX:** - **Name:** Fibromyalgia - **Type:** Chronic multisystem pain syndrome / Central sensitization disorder - **Date:** First formal diagnostic criteria published 1990 (ACR); current criteria 2016 - **Location:** Global (affects individuals worldwide) - **Known For:** Widespread chronic pain combined with fatigue, cognitive impairment, and sleep disturbances **TAGS:** chronic pain, central sensitization, rheumatology, fatigue, cognitive dysfunction, multidisciplinary treatment, diagnostic criteria, quality of life